-
-
-
-
-
-
-
Alfasigma to Acquire Intercept Pharmaceuticals (ICPT) for $19.00 per Share in Cash
-
-
-
-
-
-
-
Intercept Pharma (ICPT) Reports Positive Data in Fibrosis due to NASH from New Analysis of its Phase 3 REGENERATE Study of OCA
-
-
-
-
-
-
-
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

